https://www.selleckchem.com/pr....oducts/tinengotinib.
13,1.97]). CM also prominently reduced pulmonary inflammation (RR=1.27, 95% CI [1.12,1.44]), and improved host immune function (WBC, MD=0.92, 95% CI [0.07,1.76]; LYM, MD=0.33, 95% CI [0.08,0.57]; LYM%, MD=2.90, 95% CI [2.09,3.71]; CRP, MD=-12.66, 95% CI [-24.40, -0.92]). Meanwhile, CM did not increase the incidence of adverse reactions (RR=1.17, 95% CI [0.39,3.52]). According to the allocated data, CM has demonstrated clinical efficacy and safety on COVID-19 pneumonia, which need to be confirmed by high quality, multiple-center, la
Like
Comment
Share
